SMARCB1-deficient sinonasal adenocarcinoma is a rare variant of SWI/SNF-deficient malignancies with SMARCB1 loss and adenocarcinoma features. More than 200 high-grade epithelial sinonasal malignancies were retrieved. A total of 14 cases exhibited complete SMARCB1 (INI1) loss and glandular differentiation. SMARCA2 and SMARCA4 were normal, except for one case with a loss of SMARCA2. Next-generation sequencing (NGS) and/or fluorescence in situ hybridization (FISH) revealed an alteration in the SMARCB1 gene in 9/13 cases, while 2/13 were negative. Two tumors harbored SMARCB1 mutations in c.157C > T p.(Arg53Ter) and c.842G > A p.(Trp281Ter). One harbored ARID1B mutations in c.1469G > A p.(Trp490Ter) and MGA c.3724C > T p.(Arg1242Ter). Seven tumors had a SMARCB1 deletion. One carried an ESR1 mutation in c.644-2A > T, and another carried a POLE mutation in c.352_374del p.(Ser118GlyfsTer78). One case had a PAX3 mutation in c.44del p.(Gly15AlafsTer95). Histomorphology of SMARCB1-deficient adenocarcinoma was oncocytoid/rhabdoid and glandular, solid, or trabecular in 9/14 cases. Two had basaloid/blue cytoplasm and one showed focal signet ring cells. Yolk sac tumor-like differentiation with Schiller-Duval-like bodies was seen in 6/14 cases, with 2 cases showing exclusively reticular-microcystic yolk sac pattern. Follow-up of a maximum of 26 months (median 10 months) was available for 8/14 patients. Distant metastasis to the lung, liver, mediastinum, bone, and/or retroperitoneum was seen in 4/8 cases. Locoregional failure was seen in 75% of patients, with 6/8 local recurrences and 3 cervical lymph node metastases. At the last follow-up, 5 of 8 (62%) patients had died of their disease 2 to 20 months after diagnosis (median 8.2 months), and 3 were alive with the disease. The original diagnosis was usually high-grade non-intestinal-type adenocarcinoma or high-grade myoepithelial carcinoma. A correct diagnosis of these aggressive tumors could lead to improved targeted therapies with potentially better overall disease-specific survival.

Bioptic Laboratory Ltd Pilsen Czech Republic

Department of Anatomic Histopathology and Cytogenetics Department of Laboratory Medicine Niguarda Cancer Center Milan Italy

Department of Anatomical Pathology Queensland Health Royal Brisbane and Women Hospital University of Queensland Brisbane Australia

Department of Clinical and Molecular Pathology University Hospital and Medical Faculty of Palacky University Olomouc Czech Republic

Department of Otorhinolaryngology University Hospital in Pilsen Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Pathology Faculty of Medicine in Pilsen Charles University E Benese 13 305 99 Pilsen Czech Republic

Department of Translational Research School of Medicine University of Pisa Pisa Italy

Institute of Biomedicine Pathology University of Turku and Department of Pathology Turku University Hospital Turku Finland

Institute of Pathology University Hospital Erlangen Friedrich Alexander University Erlangen Nürnberg Erlangen Germany

Molecular and Genetic Laboratory Bioptic Laboratory Ltd Pilsen Czech Republic

Pathological Laboratories Medicyt Ltd Košice Slovak Republic

See more in PubMed

Agaimy A, Franchi A, Lund VJ, Skálová A, Bishop JA, Triantafyllou A, Andreasen S, Gnepp DR, Hellquist H, Thompson LDR, Rinaldo A, Ferlito A (2020) Sinonasal undifferentiated carcinoma (SNUC): from an entity to morphologic pattern and back again-a historical perspective. Adv Anat Pathol 27(2):51–60 10.1097/PAP.0000000000000258 PubMed DOI

Dogan S, Chute DJ, Xu B et al (2017) Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas. J Pathol 242(4):400–408 10.1002/path.4915 PubMed DOI PMC

Mito JK, Bishop JA, Sadow PM et al (2018) Immunohistochemical detection and molecular characterization of IDH-mutant sinonasal undifferentiated carcinomas. Am J Surg Pathol 42(8):1067–1075 10.1097/PAS.0000000000001064 PubMed DOI

French CA (2010) NUT midline carcinoma. Cancer Genet Cytogenet 203(1):16–20 10.1016/j.cancergencyto.2010.06.007 PubMed DOI PMC

Bishop JA, Thompson LDR, Loney EL (eds) (2022) Chapter 2: nasal, paranasal, and skull base tumours. In: WHO classification of tumours editorial board. Head and neck tumours. [Internet; beta version ahead of print]. Lyon (France): International Agency for Research on Cancer; [cited 2023 May 8]. (WHO classification of tumours series, 5th ed.; vol. 9). Available from: https://tumourclassification.iarc.who.int/chapters/52/1

Agaimy A (2023) SWI/SNF-deficient sinonasal carcinomas. Adv Anat Pathol 30(2):95–103 10.1097/PAP.0000000000000372 PubMed DOI

Agaimy A, Koch M, Lell M et al (2014) SMARCB1(INI1)-deficient sinonasal basaloid carcinoma: a novel member of the expanding family of SMARCB1-deficient neoplasms. Am J Surg Pathol 38:1274–1281 10.1097/PAS.0000000000000236 PubMed DOI PMC

Bishop JA, Antonescu CR, Westra WH (2014) SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract. Am J Surg Pathol 38:1282–1289 10.1097/PAS.0000000000000285 PubMed DOI PMC

Agaimy A, Hartmann A, Antonescu CR et al (2017) SMARCB1 (INI-1)-deficient sinonasal carcinoma: a series of 39 cases expanding the morphologic and clinicopathologic spectrum of a recently described entity. Am J Surg Pathol 41:458–471 10.1097/PAS.0000000000000797 PubMed DOI PMC

Leivo I (2016) Sinonasal adenocarcinoma: update on classifcation, immunophenotype and molecular features. Head Neck Pathol 10:68–74 10.1007/s12105-016-0694-9 PubMed DOI PMC

Leivo I (2007) Update on sinonasal adenocarcinoma: classification and advances in immunophenotype and molecular genetic make-up. Head Neck Pathol 1(1):38–43 10.1007/s12105-007-0025-2 PubMed DOI PMC

Stelow EB, Jo VY, Mills SE et al (2011) A histologic and immunohistochemical study describing the diversity of tumors classifed as sinonasal high-grade nonintestinal adenocarcinomas. Am J Surg Pathol 35:971–980 10.1097/PAS.0b013e31821cbd72 PubMed DOI

Baneckova M, Agaimy A, Andreasen S et al (2018) Mammary analog secretory carcinoma of the nasal cavity: characterization of 2 cases and their distinction from other low-grade sinonasal adenocarcinomas. Am J Surg Pathol 42(6):735–743 10.1097/PAS.0000000000001048 PubMed DOI

Klubíčková N, Mosaieby E, Ptáková N et al (n.d.) High-grade non-intestinal type sinonasal adenocarcinoma with ETV6::NTRK3 fusion, distinct from secretory carcinoma by immunoprofile and morphology. Virchows Arch 2023 in press PubMed PMC

Shah AA, Jain D, Ababneh E, Agaimy A, Hoschar AP, Griffith CC, Magliocca KR, Wenig BM, Rooper LM, Bishop JA (2020) SMARCB1 (INI-1)-deficient adenocarcinoma of the sinonasal tract: a potentially under-recognized form of sinonasal adenocarcinoma with occasional yolk sac tumor-like features. Head Neck Pathol 14(2):465–472 10.1007/s12105-019-01065-7 PubMed DOI PMC

Zamecnik M, Rychnovsky J, Syrovatka J (2018) Sinonasal SMARCB1 (INI1) deficient carcinoma with yolk sac tumor diferentiation: report of a case and comparison with INI1 expression in gonadal germ cell tumors. Int J Surg Pathol 26:245–249 10.1177/1066896917741549 PubMed DOI

Li CY, Han YM, Xu K et al (2021) Case report: SMARCB1 (INI-1)-deficient carcinoma of the nasal cavity with pure yolk sac tumor differentiation and elevated serum AFP levels. Onco Targets Ther 14:2227–2233 10.2147/OTT.S302613 PubMed DOI PMC

Hazir B, Şímsek B, Erdemír A et al (2022) Sinonasal SMARCB1 (INI1) deficient carcinoma with yolk sac tumor differentiation: a case report and treatment options. Head Neck Pathol 16:596–601 10.1007/s12105-021-01375-9 PubMed DOI PMC

Ng JKM, Chan JYK, Li JJX et al (2022) SMARCB1 (INI1)-deficient sinonasal carcinoma with yolk sac differentiation showing co-loss of SMARCA4 immunostaining- a case report and literature review. Head Neck Pathol 16:934–941 10.1007/s12105-022-01423-y PubMed DOI PMC

Skalova A, Agaimy, A, Vaněček T, Klubíčková N, Kiss, K, Baneckova M, Michal M (2023) SMARCB1-deficient sinonasal adenocarcinoma: rare variant of SWI/SNF-deficient malignancy often misclassified as high-grade non-intestinal adenocarcinoma or myoepithelial carcinoma. Laboratory Investigation, (USCAP 2022 Abstracts: Head and Neck Pathology (1014–1081)), 1072–1073. 10.1016/j.labinv.2023.100092

Reiersen DA, Pahilan ME, Devaiah AK (2012) Meta-analysis of treatment outcomes for sinonasal undifferentiated carcinoma. Otolaryngol Head Neck Surg 147:7–14 10.1177/0194599812440932 PubMed DOI

French CA (2013) The importance of diagnosing NUT midline carcinoma. Head Neck Pathol 7(1):11–16 10.1007/s12105-013-0428-1 PubMed DOI PMC

Alzumaili B, Sadow PM (2023) IDH2 -Mutated sinonasal tumors: a review. Adv Anat Pathol 30(2):104–111 10.1097/PAP.0000000000000391 PubMed DOI PMC

Agaimy A (2023) SWI/SNF-deficient Malignancies: optimal candidates for immune-oncological therapy? Adv Anat Pathol 30(3):211–217 10.1097/PAP.0000000000000366 PubMed DOI

Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, Karapetyan K, Katz K, Liu C, Maddipatla Z, Malheiro A, McDaniel K, Ovetsky M, Riley G, Zhou G, Holmes JB, Kattman BL, Maglott DR (2018) ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res 46(D1):D1062–D1067. 10.1093/nar/gkx1153 10.1093/nar/gkx1153 PubMed DOI PMC

Šteiner P, Andreasen S, Grossmann P et al (2018) Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands. Virchows Arch 473(4):471–480. 10.1007/s00428-018-2349-6 10.1007/s00428-018-2349-6 PubMed DOI

Stern M, Jensen R, Herskowitz I (1984) Five SWI genes are required for expression of the HO gene in yeast. J Mol Biol 178(4):853–68 10.1016/0022-2836(84)90315-2 PubMed DOI

Reddy D, Bhattacharya S, Workman JL (2023) (mis)-Targeting of SWI/SNF complex(es) in cancer. Cancer Metastasis Rev. 10.1007/s10555-023-10102-5 10.1007/s10555-023-10102-5 PubMed DOI PMC

Li Z, Zhao J, Tang Y (2023) Advances in the role of SWI/SNF complexes in tumours. J Cell Mol Med 27:1023–1031 10.1111/jcmm.17709 PubMed DOI PMC

Bochar DA, Wang L, Beniya H, Kinev A, Xue Y, Lane WS, Wang W, Kashanchi F, Shiekhattar R (2000) BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 102(2):257–65 10.1016/S0092-8674(00)00030-1 PubMed DOI

Lee D, Kim JW, Seo T, Hwang SG, Choi EJ, Choe J (2002) SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J Biol Chem 277(25):22330–22337 10.1074/jbc.M111987200 PubMed DOI

Mittal P, Roberts CWM (2020) The SWI/SNF complex in cancer - biology, biomarkers and therapy. Nat Rev Clin Oncol 17:435–448 10.1038/s41571-020-0357-3 PubMed DOI PMC

Brzeski J, Podstolski W, Olczak K, Jerzmanowski A (1999) Identification and analysis of the Arabidopsis thaliana BSH gene, a member of the SNF5 gene family. Nucleic Acids Res 27(11):2393–2399 10.1093/nar/27.11.2393 PubMed DOI PMC

Versteege I, Sévenet N, Lange J et al (1998) Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394:203–206 10.1038/28212 PubMed DOI

Cooper GW, Hong AL (2022) SMARCB1-Deficient cancers: novel molecular insights and therapeutic vulnerabilities. Cancers (Basel) 14(15):3645 10.3390/cancers14153645 PubMed DOI PMC

Wang N, Qin Y, Du F, Wang X, Song C (2022) Prevalence of SWI/SNF genomic alterations in cancer and association with the response to immune checkpoint inhibitors: a systematic review and meta-analysis. Gene 5(834):14663810.1016/j.gene.2022.146638 PubMed DOI

Agaimy A (2022) Proceedings of the North American Society of Head and Neck Pathology, Los Angeles, CA, March 20, 2022: SWI/SNF-deficient Sinonasal Neoplasms: An Overview. Head Neck Pathol 16(1):168–178 10.1007/s12105-022-01416-x PubMed DOI PMC

Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Malouf GG, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar AJ, Netto GJ, Rao P, Sgambato A, Maitra A, Tripathi DN, Walker CL, Karam JA, Heffernan TP, Viale A, Roberts CWM, Msaouel P, Tannir NM, Draetta GF, Genovese G (2019) p53 is a master regulator of proteostasis in SMARCB1-deficient malignant rhabdoid tumors. Cancer Cell 35(2):204-220.e9 10.1016/j.ccell.2019.01.006 PubMed DOI PMC

Ngo C, Postel-Vinay S (2022) Immunotherapy for SMARCB1-deficient sarcomas: current evidence and future developments. Biomedicines 10(3):650 10.3390/biomedicines10030650 PubMed DOI PMC

Molecularly defined sinonasal malignancies: an overview with focus on the current WHO classification and recently described provisional entities